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Abstract
Background: The prevalence of Helicobacter pylori antibiotic susceptibility in the Nepalese strains is untracked.
We determined the antibiotic susceptibility for H. pylori and analyzed the presence of genetic mutations associated
with antibiotic resistance in Nepalese strains.
Results: This study included 146 consecutive patients who underwent gastroduodenal endoscopy in Kathmandu,
Nepal. Among 42 isolated H. pylori, there was no resistance to amoxicillin and tetracycline. In contrast, similar with
typical South Asian patterns; metronidazole resistance rate in Nepalese strains were extremely high (88.1 %, 37/42).
Clarithromycin resistance rate in Nepalese strains were modestly high (21.4 %, 9/42). Most of metronidazole
resistant strains had highly distributed rdxA and frxA mutations, but were relative coincidence without a synergistic
effect to increase the minimum inhibitory concentration (MIC). Among strains with the high MIC, 63.6 % (7/11) were
associated with frameshift mutation at position 18 of frxA with or without rdxA involvement. However, based on next
generation sequencing data we found that one strain with the highest MIC value had a novel mutation in the form of
amino acid substituted at Ala-212, Gln-382, Ile-485 of dppA and Leu-145, Thr-168, Glu-117, Val-121, Arg-221 in dapF
aside from missense mutations in full-length rdxA. Mutations at Asn-87 and/or Asp-91 of the gyrA were predominantly
in levofloxacin-resistant strains. The gyrB mutation had steady relationship with the gyrA 87–91 mutations. Although
three (44.4 %) and two (22.2 %) of clarithromycin resistant strains had point mutation on A2143G and A2146G, we
confirmed the involvement of rpl22 and infB in high MIC strains without an 23SrRNA mutation.
Conclusions: The rates of resistance to clarithromycin, metronidazole and levofloxacin were high in Nepalese strains,
indicating that these antibiotics-based triple therapies are not useful as first-line treatment in Nepal. Bismuth or
non-bismuth-based quadruple regimens, furazolidone-based triple therapy or rifabutin-based triple therapy may
become alternative strategy in Nepal.
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Background
The achievement of Helicobacter pylori against very
hostile environment colonized on the stomach of over half
of the world's population enact as the most successful
human pathogens coexisted nearly sixty thousands years
[1]. Although most of individuals exhibit overt disease
leading to the hypothesis that the bacterium might be
harmless and commensally, chronic infection of H. pylori
represents a key factor in the etiology of various gastro-
intestinal diseases including chronic gastritis, peptic
ulcer and mucosa-associated lymphoid tissue lymphoma.
The outcome of each individual infection is capricious,
similar to the rate of progression of the gastric mucosal
damage. However, further progression is halted by eradica-
tion [2]. A recent meta-analysis supported that H. pylori
eradication adequately decreases the rate of gastric malig-
nancy, and the magnitude of the protective impact is more
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noteworthy among individuals with higher baseline gastric
cancer risk [3]. Nevertheless, the adequacy of the standard
first-line regimen containing a proton pump inhibitor,
amoxicillin (AMX) and clarithromycin (CAM) or metro-
nidazole (MNZ) has been seriously challenged and eradica-
tion rates below 70 % have been accounted in numerous
countries, including South Asia [4, 5].
H. pylori antibiotic resistance mechanisms have been
recognized in view of the different site-specific muta-
tions that can be distinguished by molecular methods.
It is important as a premise for consideration of more
rational antibiotic combinations. One mechanism of
CAM resistance has been elucidated due to one of five
well-known point mutations (A2142G, A2143G, A2142C,
A2144T, T2717C and C2694A) in the 23SrRNA [6, 7].
Our previous report demonstrated higher MICs associated
with the synergic effect of mutated sequences in infB
(hp1048), rpl22 (hp1314) and A2143G [8]. Additionally,
inactivation mutation including frameshift mutation, in-
sertions and deletions of the rdxA (hp0954) and frxA
(hp0642) [9]. Novel mutations including rpsU (hp0562)
[10], dppA (hp0298), dppB (hp0299), rps4 (hp1294), ackA
(hp0903), rnc (hp0662) and dapF (hp0566) were associated
with MNZ resistance [11]. On the other hand, the mech-
anism of fluoroquinolone resistance in H. pylori has been
identified to be linked to mutations in the quinolone
resistance determining regions of the gyrA and gyrB,
coding of the DNA gyrase [12]. Dual mutations in gyrA
is accounted for a greater impact, while gyrB frequently
occurred alongside gyrA mutations [13].
Nepal is a small landlocked country in South Asia with a
low incidence of gastric cancer (5.3 cases per 100,000 popu-
lations per year; GLOBOCAN 2012; http://globocan.iarc.fr).
Although it was varied between studies (16.3–70.5 %)
[14–19], we confirmed the prevalence of H. pylori in-
fection is 38.4 % (56/146) using several diagnostic test
that significantly related to source of drinking water
[20]. The majority of strains are so-called Western-type-
cagA in Nepal as similar to typical South Asian patterns
[20]. However, the mountainous people of northern
Kathmandu are culturally linked to the Buddhists of
Tibet, have higher prevalence of H. pylori infection and
high-risk gastric mucosal atrophy than those Kathmandu
people, the capital and the largest urban agglomerate of
Nepal [21]. It is suggested lay stress on the need for H.
pylori eradication in Nepal. Local antibiotic resistances
screening are a key to counter primary H. pylori treatment
failure, thus, reduce possibility spreading of secondary
antibiotic resistance [4].
The prevalence of H. pylori antibiotic susceptibility in
the Nepalese strains is untracked. Table 1 summarized H.
pylori antibiotics resistance rates in South Asia. Generally,
South Asian countries are the high CAM and MNZ resist-
ance prevalence region [5]. Moreover, India and Bangladesh
strains demonstrated emerging levofloxacin (LVX) re-
sistance [22, 23], the second-line regimen drug and as a
rescue treatment for H. pylori eradication. In recent
years, antibiotic resistance is expanding overall [24, 25],
it is critical to look at current drug resistance rates in
Nepal. In this study, we aimed to determine the anti-
biotic susceptibility of H. pylori to CAM, MNZ, AMX,
tetracycline (TCN), and LVX. Furthermore, we also de-
termined the presence of genetic mutations associated
antibiotic resistance in Nepalese strains.
Methods
Patients and H. pylori
This study included 146 consecutive patients (76 women
and 70 men; mean age of 42.2 ± 15.7 years) consecutively
from July 2012 to September 2012. The survey was con-
ducted at the endoscopy services section of the Gastro-
enterology Department, Tribhuvan University Teaching
Hospital (TUTH), Kathmandu, Nepal. Peptic ulcer dis-
eases, including gastric and duodenal ulcers, were diag-
nosed by endoscopic observation, while chronic gastritis
was determined by histologic examination. Exclusion
criteria included a history of partial gastric resection,
eradication therapy for H. pylori, and treatment with
bismuth-containing compounds, H2-receptor blockers,
or proton pump inhibitors (PPI) within four weeks
before the study.
For H. pylori culture, antral biopsy specimens were
homogenized and inoculated onto Mueller Hinton II
Agar medium (Becton Dickinson, NJ, USA) supplemented
with 7 % horse blood without antibiotics. The plates were
incubated for up to 10 days at 37 °C under microaero-
philic conditions (10 % O2, 5 % CO2, and 85 % N2). H.
pylori isolates were identified based on colony morph-
ology; Gram staining results; and positive reactions for
oxidase, catalase, and urease. Isolated strains were stored
at −80 °C in Brucella Broth (Difco, NJ, USA) containing
10 % dimethyl sulfoxide and 10 % horse serum.
Antibiotic susceptibility testing
E-test (Biomerieux, Marcy l'´Etoile, France) was used to
determine the minimum inhibitory concentration (MIC)
of AMX, MNZ, TCN, CAM, and LVX. Mueller-Hinton
II Agar medium (Becton Dickinson) supplemented with
10 % defibrinated horse blood was used as culture media.
The bacterial suspension, adjusted to be equivalent to a
McFarland opacity standard of 3.0, was inoculated onto the
plates. After 72 h of incubation, the MIC of each antibiotic
was determined. Quality control was performed using H.
pylori ATCC 43504. The resistance breakpoints were
determined as described by the European Committee
on Antimicrobial Susceptibility Testing (EUCAST; available
in http://www.eucast.org/). Strains were considered to be
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resistant for MICs >0.125 mg/L for AMX, 0.25 mg/L for
CAM, 8 mg/L for MNZ, and 1 mg/L for TCN and LVX.
Molecular detection on resistant strains
Mutations in gyrA, gyrB, rdxA, frxA and 23S rRNA were
assessed on antibiotic-resistant strains by polymerase
chain reaction (PCR) based sequencing. H. pylori DNA
was extracted from H. pylori cultured to confluence on
MNZ-resistant strains, gyrA and gyrB for LVX-resistant
strains and 23S rRNA peptidyl transferase for CAM-
resistant strains were amplified using the primers on the
Additional file 1: Table S1 as described previously
[13, 26, 27]. As a control, we sequenced randomly
selected 4-sensitive MNZ and LVX strains and 2-
sensitive CAM strains. The PCR products were ana-
lyzed by gel electrophoresis using 1.5% agarose gel
containing ethidium bromide. The sequences were then
generated to the published sequence of the H. pylori strain
26695 (GenBank accession number AE000511.1 GI:
6626253) using the MAFFT version 7 (available in
http://mafft.cbrc.jp/alignment/server/) and confirmed
by visual inspection.
To find other genetic mutations with high MIC values
but not involving typical 23S rRNA, rdxA and frxA muta-
tions, we also obtained full-length 23S rRNA, infB, rpl22
[8], rdxA, frxA, rpsU [10], dppA, dppB, rps4, ackA, rnc
and dapF [11] from next-generation sequencing (NGS)
data (MiSeq next-generation sequencer; Illumina, Inc.,
San Diego, CA). MiSeq output was integrated into contig
sequences by CLC Genomics Workbench 7.0.4. Genomics
Workbench was also used for gene prediction and transla-
tion to protein sequences.
Statistical analysis
Discrete variables were tested using the chi-square test,
while continuous variables were tested using the Mann–
Whitney U and t-tests. P values < 0.05 were considered sta-
tistically significant. The SPSS statistical software package
version 18.0 (SPSS, Inc., Chicago, IL) was used for all statis-
tical analyses.
Results
Prevalence of antibiotic resistance
The prevalence of H. pylori infection was 37.7 % (55/146)
based on histology confirmed by immunohistochemistry,
whereas using culture it was 34.9 % (51/146) [20]. However,
9 isolates did not grow when subcultured onto Mueller
Hinton II Agar medium from antibiotic selection plate.
Finally, a total of 42H. pylori strains were successfully iso-
lated; consisting 16 male (age range, 17 to 77 years; mean
age, 42.3 ± 18.9 years) and 26 female patients (age range, 17
to 69 years; mean age 43.3 ± 14.8 years). The patients con-
sisted of 35 with chronic gastritis, 4 with peptic ulcer dis-
eases and 3 with gastric cancer. Overall, only three strains
showed sensitive to all antibiotics (7.14 %). Interestingly,
there was no AMX- and TCN-resistant strains and these
strains had low MIC predominant (90.5 % for 0.016 mg/L
or less for AMX and for 0.25 mg/L or less for TCN, re-
spectively) (Table 2). In contrast, similar with typical
South Asian pattern [5]; MNZ resistance rate in Nepalese
strains showed an emerging antimicrobial resistance pat-
tern (88.1 %, 37/42) with MIC values 64 mg/L or more
(26/37, 70.3 %, Fig. 1). In addition, although CAM resist-
ance rate in Nepalese strains were modestly high (21.4 %,
9/42), we detected a high prevalence of LVX resistance
(42.9 %, 18/42) with a high distribution of great MIC
Table 1 H. pylori antibiotics resistance rates in South Asia
Ref Country City Year Patients Methods CAM MNZ LVX TCN AMX Others
[22] India Gujarat 2008–2011 80 DDM 58.8 % 83.8 % 72.5 % 53.8 % 72.5 % Ciprofloxacin (50 %)
[33] India Multicentre – 259 E-test 44.7 % 77.9 % – – 32.8 % –
[53] India Kolkata 2000–2001 67 ADM 0.0 % 85.1 % – 7.5 % 0.0 % Furazolidone (0.0 %)
[37] India North India – 68 ADM 11.8 % 48.5 % – 16.2 % 17.6 % Furazolidone (22.1 %)
[34] India Varanasi 2005–2006 63 ADM 4.7 % 100.0 0.0 % 65.1 % –
[32] Pakistan Karachi 2005–2008 178 NM 36.0 % 89.0 % – 12.0 % 37.0 % Ofloxacin (18.5 %)
[54] Pakistan Karachi 2008–2013 92 E-test 5.4 % 97.8 % 16.2 % 4.3 % 2.2 % Ofloxacin (30.1 %),
Furazolidone (15.2 %)
[55] Pakistan Karachi 2007–2009 92 E-test 32.6 % 47.8 % – – 2.2 % –
[56] Pakistan Karachi 2009–2010 162 E-test 37.0 % – – – – Fluoroquinolone 62.3 %
[35] Pakistan Rawalpindi 2011–2012 46 E-test 47.8 % 73.9 % – 4.4 % 54.3 % Ciprofloxacin (13.0 %)
[57] Bangladesh Dhaka 1999–2001 174 ADM 10.0 % 77.5 % – 15.0 % 6.6 % –
[23] Bangladesh Dhaka 2014 56 ADM 39.3 % 94.6 % 66.1 % 0.0 % 3.6 % –
Abbreviations: ADM Agar Dilution Method, DDM Disk diffusion method, E-test Epsilometer test, CAM clarithromycin, MNZ metronidazole, LVX levofloxacin, AMX
amoxicillin, TCN tetracycline
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values predominant (94.4 % of resistant strains showed
32 mg/L or more). Antibiotic resistance rate did not differ
among different age groups, gender and clinical outcomes
(P >0.05).
Overall, there was no strain resistant to all tested
antibiotics. Only five strains were resistant to triple an-
tibiotics; CAM, MNZ, and LVX (Table 3). Among all
strains, 28.6 % (12/42) showed dual-drug resistance to
MNZ and LVX. Additionally, three strains (7.1 %) were
resistant to CAM and MNZ. No differences were ob-
served in clinical outcomes between single-drug and
multidrug resistant infections (P >0.05).
Detection of H. pylori genes mutations associated with
antimicrobial resistance
The two and three MNZ-resistant strains did not show
PCR identifiable specific bands target of rdxA and frxA,
respectively. Therefore, a total 35 rdxA and 34 frxA of
MNZ-resistant strains were analyzed in this study com-
pared to 4-sensitive strains. Both of DNA sequence analysis
of rdxA and frxA from MNZ-sensitive strains revealed in-
tact reading frames (lacking nonsense mutations). Pairwise
alignment identified that the MNZ-sensitive strains shared
94.5–97.3 % and 96.5–98.6 % identity with the reference
strain, 26695 for rdxA and frxA, respectively. In contrast,
most of the rdxA of MNZ-resistant strains contained mis-
sense mutations (12/37, 32.4 %) and nonsense mutation re-
sulted premature stop codon (12/37, 32.4 %, Table 4).
Moreover, rdxA alleles of 7 strains (18.9 %) contained nu-
cleotide deletion and/or insertion that resulted in transla-
tional frameshift. The similar pattern with rdxA showed in
frxA of MNZ-resistant that also contained missense muta-
tions, premature stop codon and translational frameshift
(11/37, 29.7 %; 4/37, 10.8 % and 17/37, 45.9 %, respectively).
The association between these two genes was relative coin-
cidence without a synergistic effect to increase MIC values.




Female Male <29 30–39 40–49 50–59 >60
(n = 42) (n = 26) (n = 16) (n = 10) (n = 7) (n = 11) (n = 7) (n = 7)
AMX 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
CAM 9 (21.4) 7 (26.9) 2 (12.5) 2 (20.0) 2 (28.6) 2 (18.2) 1 (14.3) 2 (28.6)
MNZ 37 (88.1) 24 (92.3) 13 (81.3) 8 (80.0) 6 (85.7) 9 (81.8) 7 (100.0) 7 (100.0)
TNC 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
LVX 18 (42.9) 10 (38.5) 8 (50.0) 6 (60.0) 2 (28.6) 3 (27.3) 2 (28.6) 5 (71.4)
Abbreviations: AMX amoxicillin, CAM clarithromycin, MNZ metronidazole, TCN tetracycline, LVX levofloxacin
Fig. 1 Distribution of antibiotic MIC values. The resistance rates to clarithromycin, metronidazole, levofloxacin were high; in contrast with other
South Asian countries, resistance rates to amoxicillin and tetracycline were very low
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Among 7 strains with high MIC values (>256 mg/L or
more), 63.6 % strains were associated with frameshift
mutation at position 18 of frxA (7/11) with or without
rdxA involvement. Interestingly, there was no mutation
on any rdxA and frxA in one strain with high MIC
values (Nepal120).
Based on the previous report [10, 11], we performed
NGS of the Nepal120 strain (average sequencing depth
was 249.8× and overall %GC was 39.0). Nonetheless, we
could not obtain ackA and rnc from NGS data. Using strain
26695 and the control MNZ-sensitive strain Nepal145, we
could not identify any mutations in full-length frxA, dppB,
rpsU and rps4. In contrast, we revealed missense mutations
in the full-length of rdxA at Arg-90, His-97, Pro-106 and
Val-111. Moreover, we also confirmed involvement of novel
mutated sequences in the form of amino acid substituted at
Ala-212, Gln-382, Ile-485 of dppA and Leu-145, Thr-168,
Glu-117, Val-121, Arg-221 in dapF.
There was no mutation on both of gyrA and gyrB sub-
units among the control four LVX-sensitive strains.
Among 18 LVX-resistant strains, 17 had amino acid vari-
ants at gyrA subunit (Table 5). The major well-known point
mutations in the 91- and 87-positions were predominant
(15/18, 83.3 %), including 9 of LVX-resistant strains
(50.0 %) substituted amino acid at Asp-91, while six
strains had amino acid substitution at Asn-87 (33.3 %).
Other mutations included substituted amino acid at
Ala-88, Ser-63 and Arg-130. On the other hand, only
one strain exhibited amino acid substitution at Glu-483
in gyrB subunits. However, it is coincidence with gyrB
without influence to increase of MIC values. There was
no correlation between degree of LVX-resistance with
the type and number of mutations in both genes.
Based on 23S rRNA sequenced in the 9 CAM-resistant
strains exhibited 3 (44.4 %) and 2 (22.2 %) had point
mutation specifically on A2143G and A2146G, respect-
ively. In contrast, we identified minimal nucleotide vari-
ation on the CAM-sensitive strains. Interestingly, there
was no 23S rRNA mutation in four strains with high
MIC values (>256 mg/L or more). Based on the previous
report [8], we also performed next generation sequen-
cing of the Nepal90, Nepal110, Nepal114 and Nepal145
strains (average sequencing depth was 139.5×, 117.3×,
127.5×, 139.4×, respectively and overall %GC was 39.2,
39.0, 38.8, 38.9, respectively). Using strain 26695 and the
control CAM-sensitive strain Nepal44, we could not
identify any mutations in full-length 23S rRNA. We con-
firmed the involvement of novel mutated sequences in
C113T and G20A of rpl22 and some interest mutations
of infB such as G793A, C2669T, G2043T and C2784A
(Table 6).
Discussion
The AMX resistance rates in South Asia is diverse
(Table 1), we revealed there was no AMX resistance
from Nepalese isolates. Together with CAM or MNZ,
AMX is the first-line regimen for treatment of H. pylori
infection particularly as a secondary antibiotic in the low
efficacy of CAM-based triple treatment zone [28–31].
Although in general the AMX resistance is rare, the
increasing AMX primary resistance rates have been re-
ported in the neighbor’s country; India and Pakistan
[22, 32–35]. AMX is one of the most commonly used
antibiotics in recent years in Nepal as similar as ceftri-
axone and gentamycin [36]. Additionally we observed
no resistance to TCN, in contrast to studies from India
and Pakistan [22, 32, 35, 37]. TCN is used as a salvage
quadruple therapy [28, 38] and may be a useful alterna-
tive first-line regimen in Nepal. A strict regulation for
anti-microbial use is necessary to counteract failure of
these two essential antibiotics in Nepal.
Importantly, we observed a high prevalence of CAM
resistance (21.4 %) in Nepalese strains. It is overabun-
dance of the breaking points required by the Maastricht
guidelines on H. pylori infection management (>15–
20 %) [38, 39], consequently, CAM-based regimen may
insufficient as a first line treatment for H. pylori eradication
in Nepal. A meta-analysis demonstrated that utilization of
triple therapy that consist of PPI, AMX, and CAM in cases
of CAM resistance diminished the treatment efficacy by
66 % [40]. CAM is not a drug of choice in Nepalese physi-
cians related a high cost [41]. Nonetheless, other macro-
lides consumption such as erythromycin and azithromycin
used for lower respiratory infection in Nepal [41] and
become essential risk for cross-resistance to CAM [42].
Additionally, similar with other countries in Asia, there
was emerging resistance to MNZ in Nepal. MNZ is a
simple medication often utilized to treat different dis-
eases, for example, intestinal parasites and periodontal
and gynecologic [43, 44]. In Asia, only Japan, Thailand,
and Malaysia have populations with <40 % MNZ resist-
ance [5]. Therefore, regimens including MNZ are not
suitable and should not be chosen as first-line treat-
ment in Nepal.
The T2183C and A2223G transformations have been
frequently found to be the reason of observed CAM




MNZ + LVX 12 (28.6)
MNZ + CAM 3 (7.1)
Triple drugs
CAM +MNZ + LVX 5 (11.9)
Abbreviations: CAM clarithromycin, MNZ metronidazole, LVX levofloxacin
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resistance in Asian countries than those in Europe and
North America [45]. However, in Nepal we observed the
contribution of interest point change on A2143G and
A2146G, as previous reports [46, 47]. The A2143G
mutation has a much stronger effect than the A2142G
and A2142C mutations [46]. Interestingly among several
strains with high MIC values (>256 mg/L or more) with-
out 23S rRNA involvement, we confirmed novel mutated
Table 4 MIC of metronidazole resistant strains and the mutation of rdxA and frxA genes
No Strains MIC (mg/L) rdxA frxA
1 2 48 13frameshift R86a
2 4 >256 Q11a 18frameshift
3 5 64 N73a R3T, 54frameshift
4 8 64 Q11a Q5a
5 14 32 R16H, L62V, K190a P2E, R3P, M66I, A70V
6 15 64 K2N, 4frameshift I44T, 47frameshift
7 16 48 E107R, 109frameshift W137a
8 18 128 C148Y undetermined
9 29 >256 R16H, A80T, S108A 18frameshift
10 34 64 undetermined 106frameshift
11 41 16 R16H, R41K, 43frameshift G76R, A152V
12 49 >256 C140Y 18frameshift
13 52 >256 G189S undetermined
14 55 24 L62V, S108A, S196N, Q197a P41L, E176K
15 61 12 None A15V, I144V, M66I
16 64 32 R16H, S108A, R176C, S196N None
17 70 32 K60a D2E, A85V, K178N
18 74 64 S45G 6frameshift
19 83 >256 M21V, A80T, Q119a A70V
20 84 16 Q50a R58H
21 86 96 Q50a R25T, M66I, A154T
22 89 32 Q65a A115V
23 90 64 45frameshift 18frameshift
24 92 >256 C140Y 18frameshift
25 94 64 Q50a undetermined
26 108 128 R16L 18frameshift
27 110 32 None P41L
28 113 128 A40T A16T, I44V, 70frameshift
29 114 >256 Q16a 18frameshift
30 116 >256 G163D 18frameshift
31 120b >256 None None
32 123 >256 Q50a V6a
33 124 >256 D23G 18frameshift
34 137 128 M56I, 201frameshift 70frameshift
35 140 96 60frameshift 71frameshift
36 141 64 S43L 72frameshift
37 142 64 undetermined A15V
Q11a means premature stop codon at Gln11; 13frameshift means frameshift mutation in the amino acid 13; R16H means amino acid substituted at Arg-16; None
means no specific mutation; Undetermined is the strains that failed to show identifiable specific bands of rdxA or frxA target in PCR
bHigh MIC values strain without specific mutation in rdxA and frxA but contained mutation in dppA and dapF
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sequences in rpl22 and infB in the different position than
previous publication [8]. Suggesting that rpl22 and infB
mutations might not only result in synergistic effects, but
also could be independent causes of CAM resistance. On
the other hand, we recognized diverse mutations involving
the rdxA and frxA in the large part MNZ-resistant-strains;
appear differently in relation to against MNZ-sensitive
strains. Additionally, several strains with high MIC values
were associated with a framing error in position 18 of frxA
that may become a particular mutation site of Nepalese
MNZ-resistant strains. Finally, we introduced the novel
mutation in dppA and dapF in addition to rdxA mutations
but irrespective of frxA and rpsU mutations. Unlike dapF
which is associated with biosynthesis of lysine and pep-
tidoglycan [48], dppA has a role in the transportation of
dipeptide ATP-binding cassette on a drug efflux pump
[11] that eventually lead to MNZ resistance.
Several guidelines proposed that LVX ought to be uti-
lized as a part of rescue treatment based on antibiotic
susceptibility testing [28, 38, 49]. However, our findings
showed a high prevalence of primary resistance to LVX
that may also prompt cross-resistance with other fluor-
oquinolones. It is become a serious challenge and may
reduce the efficacy of treatment with LVX-based regi-
mens in Nepal. In addition, together with MNZ, LVX is
the most commonly observed as multidrug resistance
in Nepal. Furthermore, 5 strains were identified resistance
to triple antibiotics. H. pylori strains harboring triple or
quadruple resistance can hinder the choice and achieve-
ment of eradication regimens.
As similar with previous reports [50–52], point muta-
tions at amino acid 87 (Asn to Lys, Tyr, or Ile) and 91
(Asp to Asn, Gly, or Tyr) were also mainly found for
Nepalese strains. Interestingly, different transformations
including substituted amino acid at Ser-63 and Arg-130
also associated with high MIC values. A few mutations
and the coincidence of Glu-483 substitution in gyrB
subunits with gyrA suggested a minimum influence of
the gyrB mutations in Nepalese LVX-resistant strains.
Finally, mutation analysis at position 18 of frxA, Asn-87
and/or Asp-91 of gyrA, A2143G and A2146G of
23SrRNA will be useful as guiding follow-up of eradica-
tion after first-line regimens failure in Nepal. Recently, it
was created a high accuracy DNA strip genotyping test
combining PCR and hybridization that allows the molecu-
lar identification of mutations in the gyrA and 23SrRNA
within 6 h [47].
The number of samples in this study was relatively
low, which certainly suggests the limitations of this study.
Table 5 MIC of levofloxacin resistant strains and the mutation
of gyrA and gyrB genes
No Strains MIC (mg/L) gyrA gyrB
1 2 >32 N87K None
2 5 >32 D91G None
3 8 >32 D91N None
4 16 >32 S63P, D91N None
5 18 >32 D91N None
6 29 >32 S63P, N87K, P188S None
7 38 >32 D99V None
8 49 >32 N87K, D91N, V172I None
9 55 >32 N87I E483K
10 70 >32 None None
11 86 >32 N87K None
12 89 >32 D91N, R130K None
13 90 >32 N87K None
14 120 8 A88P None
15 123 >32 D91Y None
16 140 >32 D91N None
17 141 >32 D91N None
18 142 >32 S63P, R130K None
N87K means amino acid substituted at Asn-87; None means no specific mutation
Table 6 MIC of clarithromycin resistant strains and the mutation of 23S rRNA gene
No Strains MIC (mg/L) 23S rRNA rpl22 infB
1 5 >256 A2143G
2 29 >256 A2143G
3 49 >256 A2146G
4 89 >256 A2143G
5 90 >256 None C113T C193A, T449C, G793A, T870G, C1157T, C1988T, C2669T, A2781G, C2784A
6 92 >256 A2146G –
7 110 >256 None None C133G, G139A, C821T, A2551G, 547del, 571del
8 114 >256 None G20A A298G, G448A, G568A, A1108G, G2403T, C2669T
9 145 >256 None G20A G8A, A403G, G793A, C810A, C878T, T1171G, G2043T, C2784A, G793A, C812T
A2143G means point mutation at 2143 position; None means no specific mutation
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In addition, we only determined the presence of well-
known genetic mutations associated with antibiotic
resistance. However, our results could as a susceptibility-
guided treatment in Nepal. High prevalence of CAM,
MNZ and LVX resistance in Nepal results in prerequisite
for utilizing other alternative strategies, for example,
bismuth or non-bismuth-based quadruple regimens or
rifabutin-based triple therapy is fundamental in Nepal
(Table 7) [5]. Additional clinical trials are required to
enhance the rate of successful eradication in Nepal.
Conclusions
We revealed the rates of resistance to CAM, MNZ, and
LVX were high in Nepal, which recommends that CAM-,
MNZ-, and LVX-based triple therapies are not useful as
first-line treatment in Nepal. TCN can be still utilized, al-
beit local information regarding its successful eradication
rate is inadequate. Bismuth or non-bismuth-based quad-
ruple regimens, furazolidone-based triple therapy or
rifabutin-based triple therapy may become alternative
strategy after first-line regimens failure in Nepal.
Additional file
Additional file 1: Table S1. The oligonucleotide primers for amplifying
rdxA, frxA, gyrA, gyrB and 23S rRNA. (DOCX 14 kb)
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